Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain‐Barré syndrome
- 24 November 2009
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 66 (5), 597-603
- https://doi.org/10.1002/ana.21737
Abstract
Objective Intravenous immunoglobulin (IVIg) is the first choice treatment for Guillain‐Barré syndrome (GBS). All patients initially receive the same arbitrary dose of 2g per kg body weight. Not all patients, however, show a good recovery after this standard dose. IVIg clearance may depend on disease severity and vary between individuals, implying that this dose is suboptimal for some patients. In this study, we determined whether the pharmacokinetics of IVIg is related to outcome in GBS. Methods We included 174 GBS patients who had previously participated in 2 randomized clinical trials. At entry, all patients were unable to walk unaided and received a standard dose of IVIg. Total IgG levels in serum samples obtained immediately before and 2 weeks after the start of IVIg administration were determined by turbidimetry and related to clinical outcome at 6 months. Results The increase in serum IgG (ΔIgG) 2 weeks after IVIg treatment varied considerably between patients (mean, 7.8g/L; standard deviation, 5.6g/L). Patients with a low ΔIgG recovered significantly more slowly, and fewer reached the ability to walk unaided at 6 months (log‐rank p < 0.001). In multivariate analysis adjusted for other known prognostic factors, a low ΔIgG was independently associated with poor outcome (p = 0.022). Interpretation After a standard dose of IVIg treatment, GBS patients show a large variation in pharmacokinetics, which is related to clinical outcome. This may indicate that patients with a small increase in serum IgG level may benefit from a higher dosage or second course of IVIg. Ann Neurol 2009;66:597–603Keywords
This publication has 27 references indexed in Scilit:
- Immunotherapy for Guillain-Barre syndrome: a systematic reviewBrain, 2007
- Pharmacokinetics of Intravenous Immunoglobulin: A Systematic ReviewPharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2006
- Guillain-Barré syndromeThe Lancet, 2005
- Intravenous Immunoglobulin in Autoimmune Neuromuscular DiseasesJAMA, 2004
- Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndromeThe Lancet, 1997
- A Randomized Trial Comparing Intravenous Immune Globulin and Plasma Exchange in Guillain–Barré SyndromeThe New England Journal of Medicine, 1992
- Treatment related fluctuations in Guillain-Barre syndrome after high-dose immunoglobulins or plasma-exchange.Journal of Neurology, Neurosurgery & Psychiatry, 1991
- Assessment of current diagnostic criteria for Guillain-Barr syndromeAnnals of Neurology, 1990
- Plasmapheresis and acute Guillain‐Barre syndromeNeurology, 1985
- Diagnostic considerations in Guillain-Barré syndromeAnnals of Neurology, 1981